Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
151 hedge funds and large institutions have $520M invested in Sciclone Pharmaceuticals Inc in 2016 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 48 increasing their positions, 50 reducing their positions, and 27 closing their positions.
37% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 27
19% more capital invested
Capital invested by funds: $435M → $520M (+$84.5M)
6% more funds holding
Funds holding: 143 → 151 (+8)
4% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 50
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$33.4M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$8.03M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.24M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$4.6M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$12.7M |
| 2 |
Millennium Management
New York
|
-$8.13M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$6.08M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.34M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$3.61M |
SCLN Hedge Fund Activity: Q2 2016 in Review
151 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q2 2016, worth a combined $520M — up 19% from $435M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new SCLN positions and 27 closed out — a net gain of 10 holders — while 48 added to existing stakes and 50 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $33.4M. The largest seller was Stonepine Capital Management, cutting an estimated $12.7M.
- 151 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q2 2016, up from 143 in Q1 2016.
- Funds reported $520M of Sciclone Pharmaceuticals Inc stock for Q2 2016, up 19% quarter-over-quarter.
- 37 funds opened new Sciclone Pharmaceuticals Inc positions in Q2 2016 and 27 closed out, a net change of +10 holders.
- The largest Sciclone Pharmaceuticals Inc buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $33.4M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q2 2016 was Stonepine Capital Management, an estimated $12.7M sold.
Based on aggregated 13F filings for Q2 2016.